Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
Masaki ShimizuN InoueM MizutaY NakagishiA YachiePublished in: Clinical and experimental immunology (2017)
To investigate the clinical significance of soluble tumour necrosis factor receptor (sTNF-R) II/I ratio as an indicator of the diagnosis of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (s-JIA), we measured the serum sTNF-RI and II levels in 117 patients with s-JIA, including 29 patients with MAS, 15 with Epstein-Barr virus-induced haemophagocytic lymphohistiocytosis (EBV-HLH), 15 with Kawasaki disease (KD) and 28 healthy controls (HCs). We determined their correlation with measurements of disease activity and severity. Furthermore, we measured serum interleukin (IL)-18 levels in patients with EBV-HLH and compared these in levels in patients with MAS. The sTNF-RII/I ratio was elevated significantly in MAS and EBV-HLH patients compared with those in the acute phase of s-JIA and KD patients, whereas there were no significant differences between HCs and those in the acute phase of s-JIA. The sTNF-RII/I ratio increased profoundly as MAS developed and correlated positively with disease activity. Serum IL-18 levels were elevated significantly in MAS patients compared with EBV-HLH patients. The monitoring of serum IL-18 and sTNF-RII/I might be useful for the diagnosis of MAS and the differentiation between MAS and EBV-HLH.
Keyphrases
- juvenile idiopathic arthritis
- epstein barr virus
- disease activity
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- systemic lupus erythematosus
- diffuse large b cell lymphoma
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- adipose tissue
- rheumatoid arthritis patients
- oxidative stress
- drug induced
- patient reported
- high glucose
- binding protein